Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 192

1.

The many faces of asthma-chronic obstructive pulmonary disease overlap.

Boulet LP, Hanania NA.

Curr Opin Pulm Med. 2019 Jan;25(1):1-10. doi: 10.1097/MCP.0000000000000547.

PMID:
30461532
2.

COPD Management in the Primary Care Setting.

Skolnik N, Kaplan AG, Lake T, Hayden ML, Hanania NA.

J Fam Pract. 2018 Oct;67(10 Suppl):S27-S32. No abstract available.

PMID:
30423008
3.

Targeting lipid mediators in asthma: time for reappraisal.

Diamant Z, Aalders W, Parulekar A, Bjermer L, Hanania NA.

Curr Opin Pulm Med. 2019 Jan;25(1):121-127. doi: 10.1097/MCP.0000000000000544.

PMID:
30422894
4.

The Role of Inhalation Delivery Devices in COPD: Perspectives of Patients and Health Care Providers.

Hanania NA, Braman S, Adams SG, Adewuya R, Ari A, Brooks J, Mahler DA, Ohar JA, Peters J, Sanjar S.

Chronic Obstr Pulm Dis. 2018 Apr 1;5(2):111-123. doi: 10.15326/jcopdf.5.2.2017.0168.

5.

Confronting the Challenge of COPD: What Is New in the Approaches to Diagnosis, Treatment, and Patient Outcomes.

Han MK, Hanania NA, Martinez FJ.

Chest. 2018 Oct;154(4):984-985. doi: 10.1016/j.chest.2018.08.1024.

PMID:
30290933
6.

New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension delivery technology.

D'Urzo AD, Cazzola M, Hanania NA, Buhl R, Maleki-Yazdi MR.

Int J Chron Obstruct Pulmon Dis. 2018 Sep 7;13:2805-2819. doi: 10.2147/COPD.S113306. eCollection 2018. Review.

7.

Impact of doxofylline compared to theophylline in asthma: A pooled analysis of functional and clinical outcomes from two multicentre, double-blind, randomized studies (DOROTHEO 1 and DOROTHEO 2).

Calzetta L, Hanania NA, Dini FL, Goldstein MF, Fairweather WR, Howard WW, Cazzola M.

Pulm Pharmacol Ther. 2018 Dec;53:20-26. doi: 10.1016/j.pupt.2018.09.007. Epub 2018 Sep 13.

8.

Asthma COPD overlap: Impact of associated comorbidities.

Maselli DJ, Hanania NA.

Pulm Pharmacol Ther. 2018 Oct;52:27-31. doi: 10.1016/j.pupt.2018.08.006. Epub 2018 Aug 30. Review.

PMID:
30172866
9.

Clinical Approach to the Therapy of Asthma-COPD Overlap.

Maselli DJ, Hardin M, Christenson SA, Hanania NA, Hersh CP, Adams SG, Anzueto A, Peters JI, Han MK, Martinez FJ.

Chest. 2018 Aug 2. pii: S0012-3692(18)31129-2. doi: 10.1016/j.chest.2018.07.028. [Epub ahead of print] Review.

PMID:
30077690
10.

Test Performance Characteristics of the AIR, GAD-7 and HADS-Anxiety Screening Questionnaires for Anxiety in Chronic Obstructive Pulmonary Disease.

Baker AM, Holbrook JT, Yohannes AM, Eakin MN, Sugar EA, Henderson RJ, Casper AS, Kaminsky DA, Rea AL, Mathews AM, Que LG, Ramsdell JW, Gerald LB, Wise RA, Hanania NA; for American Lung Association Airways Clinical Research Centers.

Ann Am Thorac Soc. 2018 Jul 9. doi: 10.1513/AnnalsATS.201708-631OC. [Epub ahead of print]

PMID:
29986152
11.

Results of a Pulmonologist Survey Regarding Knowledge and Practices With Inhalation Devices for COPD.

Braman SS, Carlin BW, Hanania NA, Mahler DA, Ohar JA, Pinto-Plata V, Shah T, Eubanks D, Dhand R.

Respir Care. 2018 Jul;63(7):840-848. doi: 10.4187/respcare.05717. Epub 2018 May 1.

PMID:
29717099
12.

Results of a Patient Survey Regarding COPD Knowledge, Treatment Experiences, and Practices With Inhalation Devices.

Dhand R, Mahler DA, Carlin BW, Hanania NA, Ohar JA, Pinto-Plata V, Shah T, Eubanks D, Braman SS.

Respir Care. 2018 Jul;63(7):833-839. doi: 10.4187/respcare.05715. Epub 2018 Mar 20.

PMID:
29559537
13.

How does race/ethnicity influence pharmacological response to asthma therapies?

Cazzola M, Calzetta L, Matera MG, Hanania NA, Rogliani P.

Expert Opin Drug Metab Toxicol. 2018 Apr;14(4):435-446. doi: 10.1080/17425255.2018.1449833. Epub 2018 Mar 12. Review.

PMID:
29528249
14.

Anxiety and Depression in Chronic Obstructive Pulmonary Disease: Recognition and Management.

Yohannes AM, Kaplan A, Hanania NA.

Cleve Clin J Med. 2018 Feb;85(2 Suppl 1):S11-S18. doi: 10.3949/ccjm.85.s1.03. No abstract available.

15.
16.

Long-term health-related quality-of-life and symptom response profiles with arformoterol in COPD: results from a 52-week trial.

Donohue JF, Bollu VK, Stull DE, Nelson LM, Williams VS, Stensland MD, Hanania NA.

Int J Chron Obstruct Pulmon Dis. 2018 Feb 5;13:499-508. doi: 10.2147/COPD.S141729. eCollection 2018.

17.

Potential Risks Related to Modulating Interleukin-13 and Interleukin-4 Signalling: A Systematic Review.

Braddock M, Hanania NA, Sharafkhaneh A, Colice G, Carlsson M.

Drug Saf. 2018 May;41(5):489-509. doi: 10.1007/s40264-017-0636-9. Review.

18.

Measurement of fractional exhaled nitric oxide in real-world clinical practice alters asthma treatment decisions.

Hanania NA, Massanari M, Jain N.

Ann Allergy Asthma Immunol. 2018 Apr;120(4):414-418.e1. doi: 10.1016/j.anai.2018.01.031.

19.

Care pathways for the selection of a biologic in severe asthma.

Bousquet J, Brusselle G, Buhl R, Busse WW, Cruz AA, Djukanovic R, Domingo C, Hanania NA, Humbert M, Menzies Gow A, Phipatanakul W, Wahn U, Wechsler ME.

Eur Respir J. 2017 Dec 7;50(6). pii: 1701782. doi: 10.1183/13993003.01782-2017. Print 2017 Dec. No abstract available.

PMID:
29217605
20.

Trends in 30-day readmission rates after COPD hospitalization, 2006-2012.

Goto T, Faridi MK, Gibo K, Toh S, Hanania NA, Camargo CA Jr, Hasegawa K.

Respir Med. 2017 Sep;130:92-97. doi: 10.1016/j.rmed.2017.07.058. Epub 2017 Jul 26.

21.

Procalcitonin in Chronic Obstructive Pulmonary Disease Exacerbations: Is It Ready for Primetime Use?

Narendra DK, Hanania NA.

Ann Am Thorac Soc. 2017 Dec;14(12):1757-1758. doi: 10.1513/AnnalsATS.201708-673ED. No abstract available.

PMID:
29192825
22.

Examining the Effects of Age on Health Outcomes of Chronic Obstructive Pulmonary Disease: Results From the Genetic Epidemiology of Chronic Obstructive Pulmonary Disease Study and Evaluation of Chronic Obstructive Pulmonary Disease Longitudinally to Identify Predictive Surrogate Endpoints Cohorts.

Parulekar AD, Martinez C, Tsai CL, Locantore N, Atik M, Yohannes AM, Kao CC, Al-Azzawi H, Mohsin A, Wise RA, Foreman MG, Demeo DL, Regan EA, Make BJ, Boriek AM, Wiener LE, Hanania NA.

J Am Med Dir Assoc. 2017 Dec 1;18(12):1063-1068. doi: 10.1016/j.jamda.2017.09.028.

23.

Controversies and opportunities in severe asthma.

Humbert M, Busse W, Hanania NA.

Curr Opin Pulm Med. 2018 Jan;24(1):83-93. doi: 10.1097/MCP.0000000000000438. Review.

PMID:
29059087
24.

The road to precision medicine in asthma: challenges and opportunities.

Hanania NA, Diamant Z.

Curr Opin Pulm Med. 2018 Jan;24(1):1-3. doi: 10.1097/MCP.0000000000000444. No abstract available.

PMID:
29045293
25.

Targeting the interleukin-4 and interleukin-13 pathways in severe asthma: current knowledge and future needs.

Parulekar AD, Kao CC, Diamant Z, Hanania NA.

Curr Opin Pulm Med. 2018 Jan;24(1):50-55. doi: 10.1097/MCP.0000000000000436. Review.

PMID:
29036019
26.

Step-Down Therapy for Asthma Well Controlled on Inhaled Corticosteroid and Long-Acting Beta-Agonist: A Randomized Clinical Trial.

Rogers L, Sugar EA, Blake K, Castro M, Dimango E, Hanania NA, Happel KI, Peters SP, Reibman J, Saams J, Teague WG, Wise RA, Holbrook JT; American Lung Association Airways Clinical Research Centers.

J Allergy Clin Immunol Pract. 2018 Mar - Apr;6(2):633-643.e1. doi: 10.1016/j.jaip.2017.07.030. Epub 2017 Sep 30.

PMID:
28974349
27.

Predictive Biomarkers for Asthma Therapy.

Medrek SK, Parulekar AD, Hanania NA.

Curr Allergy Asthma Rep. 2017 Sep 19;17(10):69. doi: 10.1007/s11882-017-0739-5. Review.

PMID:
28929293
28.

Obesity modulates diaphragm curvature in subjects with and without COPD.

Boriek AM, Lopez MA, Velasco C, Bakir AA, Frolov A, Wynd S, Babb TG, Hanania NA, Hoffman EA, Sharafkhaneh A.

Am J Physiol Regul Integr Comp Physiol. 2017 Nov 1;313(5):R620-R629. doi: 10.1152/ajpregu.00173.2017. Epub 2017 Sep 13.

29.

Emerging inhaled long-acting beta-2 adrenoceptor agonists for the treatment of COPD.

Monaco TJ, Hanania NA.

Expert Opin Emerg Drugs. 2017 Sep;22(3):285-299. doi: 10.1080/14728214.2017.1367382. Epub 2017 Sep 3. Review.

PMID:
28868931
30.

Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma.

Casale TB, Chipps BE, Rosén K, Trzaskoma B, Haselkorn T, Omachi TA, Greenberg S, Hanania NA.

Allergy. 2018 Feb;73(2):490-497. doi: 10.1111/all.13302. Epub 2017 Sep 23.

31.

Erratum: Erratum: Efficacy of Formoterol Fumarate Delivered by Metered Dose Inhaler Using Co-Suspension™ Delivery Technology Versus Foradil® Aerolizer® in Moderate-To-Severe COPD: A Randomized, Dose-Ranging Study.

Sethi S, Fogarty C, Hanania NA, Martinez FJ, Rennard S, Fries M, Orevillo C, Darken P, St Rose E, Strom S, Fischer T, Golden M, Dwivedi S, Reisner C.

Chronic Obstr Pulm Dis. 2017 Apr 15;4(3):258. doi: 10.15326/jcopdf.4.3.2016.0158.

32.

Efficacy of Formoterol Fumarate Delivered by Metered Dose Inhaler Using Co-Suspension™ Delivery Technology Versus Foradil® Aerolizer® in Moderate-To-Severe COPD: A Randomized, Dose-Ranging Study.

Sethi S, Fogarty C, Hanania NA, Martinez FJ, Rennard S, Fries M, Orevillo C, Darken P, St Rose E, Strom S, Fischer T, Golden M, Dwivedi S, Reisner C.

Chronic Obstr Pulm Dis. 2016 Nov 17;4(1):21-33. doi: 10.15326/jcopdf.4.1.2016.0158. Erratum in: Chronic Obstr Pulm Dis. 2017 Apr 15;4(3):258.

33.

Guiding Principles for the Use of Nebulized Long-Acting Beta2-Agonists in Patients with COPD: An Expert Panel Consensus.

Wise RA, Acevedo RA, Anzueto AR, Hanania NA, Martinez FJ, Ohar JA, Tashkin DP.

Chronic Obstr Pulm Dis. 2016 Nov 15;4(1):7-20. doi: 10.15326/jcopdf.4.1.2016.0141.

34.

Factors associated with depressive symptoms in uncontrolled asthmatics.

Mangold R, Salzman GA, Williams KB, Hanania NA.

J Asthma. 2018 May;55(5):555-560. doi: 10.1080/02770903.2017.1350968. Epub 2017 Sep 7.

PMID:
28759275
35.

Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis.

Cazzola M, Rogliani P, Calzetta L, Hanania NA, Matera MG.

COPD. 2017 Oct;14(5):552-563. doi: 10.1080/15412555.2017.1347918. Epub 2017 Jul 28. Review.

PMID:
28753070
36.

The Association of Depressive Symptoms With Rates of Acute Exacerbations in Patients With COPD: Results From a 3-year Longitudinal Follow-up of the ECLIPSE Cohort.

Yohannes AM, Mülerová H, Lavoie K, Vestbo J, Rennard SI, Wouters E, Hanania NA.

J Am Med Dir Assoc. 2017 Nov 1;18(11):955-959.e6. doi: 10.1016/j.jamda.2017.05.024. Epub 2017 Jul 18.

PMID:
28733182
37.

Effect of Yoga Breathing (Pranayama) on Exercise Tolerance in Patients with Chronic Obstructive Pulmonary Disease: A Randomized, Controlled Trial.

Kaminsky DA, Guntupalli KK, Lippmann J, Burns SM, Brock MA, Skelly J, DeSarno M, Pecott-Grimm H, Mohsin A, LaRock-McMahon C, Warren P, Whitney MC, Hanania NA.

J Altern Complement Med. 2017 Sep;23(9):696-704. doi: 10.1089/acm.2017.0102. Epub 2017 Jul 17.

38.

Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with chronic obstructive pulmonary disease.

Hanania NA, Tashkin DP, Kerwin EM, Donohue JF, Denenberg M, O'Donnell DE, Quinn D, Siddiqui S, Orevillo C, Maes A, Reisner C.

Respir Med. 2017 May;126:105-115. doi: 10.1016/j.rmed.2017.03.015. Epub 2017 Mar 12.

39.

Safety of inhaled long-acting anti-muscarinic agents in COPD.

Hanania NA, Lareau SC, Yawn BP.

Postgrad Med. 2017 Jun;129(5):500-512. doi: 10.1080/00325481.2017.1317575. Epub 2017 Apr 20. Review.

PMID:
28395575
40.

Factors Determining In Vitro Lung Deposition of Albuterol Aerosol Delivered by Ventolin Metered-Dose Inhaler.

Biswas R, Hanania NA, Sabharwal A.

J Aerosol Med Pulm Drug Deliv. 2017 Aug;30(4):256-266. doi: 10.1089/jamp.2015.1278. Epub 2017 Feb 3.

41.

Assessing Patient and Provider Perceptions of Factors Associated with Patient Engagement in Asthma Care.

Sapir T, Moreo KF, Greene LS, Simone LC, Carter JD, Mateka JJL, Hanania NA.

Ann Am Thorac Soc. 2017 May;14(5):659-666. doi: 10.1513/AnnalsATS.201608-602OC.

PMID:
28128966
42.

Revisiting Type 2-high and Type 2-low airway inflammation in asthma: current knowledge and therapeutic implications.

Robinson D, Humbert M, Buhl R, Cruz AA, Inoue H, Korom S, Hanania NA, Nair P.

Clin Exp Allergy. 2017 Feb;47(2):161-175. doi: 10.1111/cea.12880. Review.

PMID:
28036144
43.

Fungal Sensitization Is Associated with Increased Risk of Life-Threatening Asthma.

Medrek SK, Kao CC, Yang DH, Hanania NA, Parulekar AD.

J Allergy Clin Immunol Pract. 2017 Jul - Aug;5(4):1025-1031.e2. doi: 10.1016/j.jaip.2016.11.015. Epub 2016 Dec 22.

PMID:
28017627
44.

Generic medications in precision medicine in asthma.

Diamant Z, Hanania NA.

Curr Opin Pulm Med. 2017 Jan;23(1):1-2. No abstract available.

PMID:
27902500
45.

An Official American Thoracic Society Workshop Report: Evaluation and Management of Asthma in the Elderly.

Skloot GS, Busse PJ, Braman SS, Kovacs EJ, Dixon AE, Vaz Fragoso CA, Scichilone N, Prakash YS, Pabelick CM, Mathur SK, Hanania NA, Moore WC, Gibson PG, Zieman S, Ragless BB; ATS ad hoc Committee on Asthma in the Elderly.

Ann Am Thorac Soc. 2016 Nov;13(11):2064-2077.

46.

Role of biologics targeting type 2 airway inflammation in asthma: what have we learned so far?

Parulekar AD, Diamant Z, Hanania NA.

Curr Opin Pulm Med. 2017 Jan;23(1):3-11. Review.

PMID:
27820746
47.

Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials.

Hanania NA, Korenblat P, Chapman KR, Bateman ED, Kopecky P, Paggiaro P, Yokoyama A, Olsson J, Gray S, Holweg CT, Eisner M, Asare C, Fischer SK, Peng K, Putnam WS, Matthews JG.

Lancet Respir Med. 2016 Oct;4(10):781-796. doi: 10.1016/S2213-2600(16)30265-X. Epub 2016 Sep 5.

PMID:
27616196
48.

Obesity Is Associated With Increased Morbidity in Moderate to Severe COPD.

Lambert AA, Putcha N, Drummond MB, Boriek AM, Hanania NA, Kim V, Kinney GL, McDonald MN, Brigham EP, Wise RA, McCormack MC, Hansel NN; COPDGene Investigators.

Chest. 2017 Jan;151(1):68-77. doi: 10.1016/j.chest.2016.08.1432. Epub 2016 Aug 25.

49.

Acute Exacerbations and Lung Function Loss in Smokers with and without Chronic Obstructive Pulmonary Disease.

Dransfield MT, Kunisaki KM, Strand MJ, Anzueto A, Bhatt SP, Bowler RP, Criner GJ, Curtis JL, Hanania NA, Nath H, Putcha N, Roark SE, Wan ES, Washko GR, Wells JM, Wendt CH, Make BJ; COPDGene Investigators.

Am J Respir Crit Care Med. 2017 Feb 1;195(3):324-330. doi: 10.1164/rccm.201605-1014OC.

50.

Common Genetic Polymorphisms Influence Blood Biomarker Measurements in COPD.

Sun W, Kechris K, Jacobson S, Drummond MB, Hawkins GA, Yang J, Chen TH, Quibrera PM, Anderson W, Barr RG, Basta PV, Bleecker ER, Beaty T, Casaburi R, Castaldi P, Cho MH, Comellas A, Crapo JD, Criner G, Demeo D, Christenson SA, Couper DJ, Curtis JL, Doerschuk CM, Freeman CM, Gouskova NA, Han MK, Hanania NA, Hansel NN, Hersh CP, Hoffman EA, Kaner RJ, Kanner RE, Kleerup EC, Lutz S, Martinez FJ, Meyers DA, Peters SP, Regan EA, Rennard SI, Scholand MB, Silverman EK, Woodruff PG, O'Neal WK, Bowler RP; SPIROMICS Research Group; COPDGene Investigators.

PLoS Genet. 2016 Aug 17;12(8):e1006011. doi: 10.1371/journal.pgen.1006011. eCollection 2016 Aug.

Supplemental Content

Loading ...
Support Center